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Vascular endothelial growth factors (VEGFs) are key regulators of permeability. The principal evidence behind how they increase vascular
permeability in vivo and in vitro and the consequences of that increase are addressed here. Detailed analysis of the published literature has
shown that in vivo and in vitro VEGF-mediated permeability differs in its time course, but has common involvement of many speciﬁc signalling
pathways, in particular VEGF receptor-2 activation, calcium inﬂux through transient receptor potential channels, activation of phospholipase
C gamma and downstream activation of nitric oxide synthase. Pathways downstream of endothelial nitric oxide synthase appear to involve
the guanylyl cyclase-mediated activation of the Rho–Rac pathway and subsequent involvement of junctional signalling proteins such as vas-
cular endothelial cadherin and the tight junctional proteins zona occludens and occludin linked to the actin cytoskeleton. The signalling
appears to be co-ordinated through spatial organization of the cascade into a signalplex, and arguments for why this may be important
are considered. Many proteins have been identiﬁed to be involved in the regulation of vascular permeability by VEGF, but still the mechan-
isms through which these are thought to interact to control permeability are dependent on the experimental system, and a synthesis of
existing data reveals that in intact vessels the co-ordination of the pathways is still not understood.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords VEGF † Vascular permeability † Calcium † Capillary † Endothelium
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Importance of vascular
endothelial growth factor-mediated
permeability in health and disease
The discovery of vascular endothelial growth factor (VEGF) in the
1980s reﬂects to some degree the continuing revision of our under-
standing of what this critical molecule does in humans, its mechanisms
of action, and its cellular targets. For, while VEGF was originally pur-
iﬁed as a tumour-secreted factor, it was done so using an assay
designed not for vessel growth but increased extravasation of dye.
Thus, it was termed vascular permeability factor by Dvorak and
Senger when they partially puriﬁed it,
1 although neither investigator
measured its effect on vascular permeability per se.
2 It was sub-
sequently also identiﬁed in 1989
3 to be the long sought after
tumour angiogenesis factor
4 separately by two endocrinologists
who had recently worked in the same laboratory (Ferrara and the
late Plouet, who both worked with Denis Gospadorowicz at UCSF
in 1988), and was termed vasculotropin by Plouet et al.
5 and VEGF
by Ferrara and co-workers.
6,7 However, VEGF acts on many cell
types, including epithelial,
8 nerve,
9 and tumour cells
10 and can act as
either a stimulator
6 or inhibitor of endothelial cell growth.
11 Our
understanding has therefore undergone such a radical revision since
1989 that the term VEGF now applies to a molecule that may or
may not be either vascular, endothelial, or growth speciﬁc.
Subsequent investigations on how VEGF acts to increase vascular
permeability are also complex, confusing, and in many cases contra-
dictory. This review will attempt to pull together much of the work
on how VEGF acts to increase vascular permeability, and what its
role is in health and disease.
1.1 What is VEGF?
The VEGF family of proteins consists in humans of ﬁve separate gene
products, termed VEGF-A (or VEGF), VEGF-B,
12 VEGF-C,
13
VEGF-D,
14 and placental growth factor (PlGF).
15 They are members
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proteins that are characterized by eight cysteines that form stable
dimeric bonds resulting in dimers in a head to tail conformation.
16
VEGF-A can be generated by almost all cells under hypoxic
17 or
other stress conditions,
18 including endothelial cells,
19 and are highly
expressed in tissues undergoing growth or remodelling including
cancers,
20 atherosclerosis,
21 and during remodelling of the female
reproductive cycle.
22 All ﬁve human VEGFs are generally alternatively
spliced to form multiple isoforms with widely varying properties.
1.2 How do VEGFs work?
VEGFs act through ligand binding to their cognate VEGF receptors, in
particular VEGFR1 (ﬂt-1),
23 VEGFR2 (ﬂk1 in the mouse, KDR in the
human),
24 and VEGFR3 (ﬂt4).
25 All three receptors can be used by
various isoforms of the various genes to signal to increase vascular
permeability, angiogenesis, and other actions of VEGFs. All the recep-
tors act by homo- and heterodimerization and activation of an intra-
cellular tyrosine kinase activity, recruitment of SH2 domain binding
proteins, and subsequent downstream signalling through multiple
common signalling pathways.
26 The link between these signalling path-
ways and vascular permeability regulation is, however, not so clear.
1.3 What is their effect?
The effects of VEGF on endothelial cells are profound, complex, and
not simple to interpret. It is clearly a potent, though not very power-
ful, endothelial growth factor. It is a potent and powerful vascular per-
meabilizing agent,
27 and a potent vasodilator.
28 It increases migration
of endothelial cells, new vessel formation,
29 and has effects on the
pericytes that surround endothelial cells,
30 and on the matrix metal-
loproteinases secreted by endothelial cells.
31 The net result of treat-
ment with VEGF is hypotension when given centrally,
32 leakage of
ﬂuid and protein from the vasculature to the tissue when secreted
locally,
33 and chaotically increased vascular growth if given alone.
34
However, to understand the published evidence on how VEGF acts
to increase vascular permeability it is necessary to deﬁne what we
mean by vascular permeability.
2. What is permeability?
2.1 Permeability coefﬁcients
The permeability of the vasculature is a property of the capillary wall
to impede movement of ﬂuid or solutes driven by a physical force. It is
a primary contributor to the regulation of exchange of nutrients and
water between tissues and blood. The other primary contributors,
which are not dependent on the barrier, include size of the physical
forces (pressure for convective ﬂux of ﬂuid and concentration gradi-
ent for diffusion of solutes) and surface area of the available barrier.
Thus it is critical to identify whether parameters being measured
during experiments to identify mechanisms through which VEGF
acts are ones that affect properties of the barrier wall or are indepen-
dent of it. This includes the hydrostatic pressure of capillaries and the
interstitium, plasma and interstitial colloid osmotic pressure, concen-
tration gradient of solutes acting across the vessel wall, and the
number of capillaries being perfused. All these can be altered by chan-
ging blood ﬂow to a tissue independently of changes in the barrier
wall and VEGF being a potent vasodilator indicates that separation
of a haemodynamic from barrier characteristics is critical for appropri-
ate interpretation of these experiments.
There are three principal permeability coefﬁcients of the capillary
wall that can be used to indicate the quality of the barrier to
impede ﬂow of ﬂuid or solutes.
2.1.1 Lp—hydraulic conductivity
The ﬂuid ﬂow per unit pressure gradient driving ﬂuid across the
barrier is the hydraulic conductivity. This parameter can be measured
relatively straightforwardly in vitro and in vivo by determining the ﬂow
rate at speciﬁc hydrostatic or osmotic pressures across the vascular
wall. In continuous capillaries, the pathway is thought to reside in
the intercellular clefts of the vascular wall,
35 although a signiﬁcant pro-
portion (up to 20%) may be across the plasma membrane and through
the cell.
36 In fenestrated capillaries (glomerulus, synovium, salivary
gland), the pathway will be dominated by the fenestra which have a
high hydraulic conductivity and surface area relative to the intercellu-
lar clefts.
37 In endothelial cells in culture, the hydraulic conductivity
will depend on conﬂuence, and the basement membrane may come
into play when measurements are made at higher pressures as the
cells compress the basement membrane a ‘sealing’ effect may be
seen.
38
2.1.2 Ps—solute permeability
Solute permeability is the solute ﬂux by diffusion per unit concen-
tration gradient per unit area.
39 The caveat ‘by diffusion’ is critical
here, as solutes may also be carried across the vessel wall by convec-
tion, and therefore if the convective ﬂux is not accounted for the per-
meability calculated is overestimated (apparent permeability).
40 Ps can
be measured in vivo and in vitro, often by extrapolating measurements
of apparent permeability back to the point at which ﬂow would
cease.
41
2.1.3 Oncotic reﬂection coefﬁcient (s)
A mixture of large and small molecular weight molecules will exert an
osmotic pressure across a semi-permeable membrane proportional
to the size of the channels through which molecules may cross.
42
Thus if the membrane is permeable to water but not solutes, then
the solution will exert its full osmotic pressure (and hence s ¼ 1).
If the membrane is freely permeable to all solutes, then no osmotic
pressure can be exerted and s ¼ 0. The inverse of s is the sieving
coefﬁcient.
2.2 Measurement of the effect of VEGF
on permeability
The effect of VEGF on permeability has been investigated using both
in vitro and in vivo models.
2.2.1 In vitro
The permeability of endothelial monolayers has been extensively
studied, but using three principal methodologies—measurement of
hydraulic conductivity (Lp),
43,44 transendothelial electrical resistance
(TEER),
45,46 and albumin transport (Palb).
44,47 Lp is measured as
described above (ﬂuid ﬂow per unit pressure per unit area of mem-
brane). TEER is the current per unit voltage applied and is inversely
proportional to the permeability to the principal charged ions (Na
and Cl). Palb is usually measured by adding labelled albumin (often
ﬂuorescent) to one side of a monolayer and measuring the amount
on the well on the other side of the layer. Using these three assays,
the effect of VEGF has been shown to increase permeability in all
three models, and there are a number of biochemical studies that
VEGFs and vascular permeability 263have been carried out to investigate the mechanisms (described
below). In most, but not all,
44 studies of cultured endothelial cells,
treatment with VEGF results in increased Lp
48 or Ps (to either Na
or albumin)
44 that develops over a period of 1 h, peaks, and then a
second wave occurs between 1 and 4 h (Figure 1).
44,46,49 This has
been shown for venous arterial and capillary endothelial cells, for
cells from the brain,
50 glomerulus,
45 aorta, retina,
44 skin,
48 umbilical
cord,
44 and many other endothelial cell types. One caveat, however,
is that in almost all in vitro models permeability is usually signiﬁcantly
higher than in in vivo equivalents. This needs to be borne in mind
when interpreting data from monolayers in culture.
51
2.2.2 In vivo
In vivo measurement of the effects of VEGF on barrier function per se
have been done by the measurement of solute permeability to
albumin,
52 by hydraulic conductivity,
53 and by oncotic reﬂection coef-
ﬁcient.
54 However, the vast majority of studies that have attempted to
investigate the effect of VEGF on permeability have used indirect
measures, and in particular the accumulation of albumin associated
dyes, or labelled albumin into the tissue.
55 These latter studies
cannot be ignored, but must be interpreted with caution. The most
widely used assay was that originally used by Senger and Dvorak to
identify VEGF,
55 which is to inject Evans’ blue incubated with
albumin into an animal, and then treat the animal, usually by subcu-
taneous injection, with VEGF or inhibitors. The tissue is then photo-
graphed, and often excised and the amount of Evans blue measured
after extraction. There are a number of assumptions that need to
be borne in mind when considering these studies.
(i) The delivery of a labelled solute to a tissue depends on the
surface area, concentration difference, and driving forces for
ﬂux across the vessel wall, as well as the permeability. Thus as
VEGF is a vasodilator,
28 it results in perfusion of more capillaries
and therefore the mechanisms through which it acts may be due
to its action as a vasodilator rather than its barrier effects.
(ii) The ﬂux of a large molecular weight molecule is primarily con-
vective under low-permeability conditions, and therefore
increased hydrostatic pressure will increase solute ﬂux, and as
again VEGF is a vasodilator it will increase hydrostatic pressure.
In addition, any agent investigated that acts to increase venous
pressure will increase post-capillary resistance and therefore
increase solute ﬂux.
(iii) Evans blue forms an equilibrium binding with albumin. It can be
.99% bound to albumin but its free dye concentration is highly
dependent on preparation and both dye and albumin concen-
tration. For instance, at 17 mM Evans blue, there is 34% free dye
in 6% albumin.
56–58 As Evans blue is 50× smaller than albumin, it
would be expected to have a permeability of at least 50× that of
albumin.
59 Moreover, while it is in equilibrium in the plasma and
predominantly bound, as soon as it crosses the vessel wall it will
again bind albumin and therefore the concentration gradient of
Evansbluewillremainhighastheinterstitialconcentrationiseffec-
tivelyzero.However,ifplasmaﬂowsslowlythroughacapillary,asit
reachestheendofthecapillarytheplasmaconcentrationwillfallas
moleculeshavediffusedintothetissue.Ifﬂowrateisincreasedthis
concentration will not fall so quickly, so maintaining a higher con-
centration difference across the vessel wall and so delivering
more Evans blue (this is of course how increasing blood ﬂow
increases oxygen delivery). This ﬂow limited solute ﬂux
60 can
explain a large proportion of Evans blue extravasation. Moreover,
as permeability increases, albumin ﬂux now also becomes ﬂow
limited, so combining increased ﬂow with increased permeability
will amplify the solute ﬂux.
(iv) Use of a single label such as Evans blue does not distinguish
between extravasated dye and dye bound to the surface layer
of the endothelium, or still in the blood, and hence increased
blood ﬂow will again contribute.
3. How does VEGF increase
permeability?
3.1 Time course
Whereas in vitro VEGF results in a slow increase in permeability
that peaks at 1 h and then a second continuing peak occurs that
Figure 1 Time course of VEGF-induced permeability. Alterations in hydraulic conductivity (Lp), solute permeability to albumin (Palb), or small
solutes such as Na ﬂuorescein (PNaF), ions (TEER) or sucrose, or sieving coefﬁcient are shown in vivo (bold) or in vitro.
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published data. Application of a single bolus of VEGF-A or VEGF-C
and measurement of hydraulic conductivity,
53,61 and solute per-
meability
52,62–66 to albumin in single capillaries/post-capillary
venules results in a very rapid and transient permeability increase
that resolves within 2–3 min. This is then followed by a longer and
more sustained increase that occurs at some point after 1 h and
lasts for up to a few days.
27,53,54,67 In contrast, application of VEGF
and measurement of solute ﬂux by Evans blue or labelled albumin
extravasation results in a slow accumulation over the ﬁrst hour,
similar to that seen in vitro.
68,69 There is thus a biphasic response to
VEGF—an initial transient increase lasting just a few minutes, and a
sustained increase that lasts many hours. The problem is deciphering
the contribution of the vasodilatory effects of VEGF towards this sus-
tained effect (the acute effect is measured in vessels where ﬂow and
driving forces are controlled, and there are very few studies measur-
ing the chronic response in the same way). The following is therefore
an account of the signalling pathways where acute and chronic
response, and in vitro vs. in vivo data are compared.
3.2 Signalling pathways
3.2.1 VEGFR activation
VEGF-A has been shown to bind to VEGFR1 and VEGFR2, and
VEGF-C binds to VEGFR2 and VEGFR3. The splice variants of
VEGF-A that are pro-angiogenic (e.g. VEGF165) act to increase Lp
in vivo (acutely),
70 Lp in vitro,
71 and albumin extravasation through
VEGFR2 activation. PlGF, which only binds VEGFR1 appears not to
increase Lp acutely.
61 VEGF-C increases Lp acutely in vivo by acting
on VEGFR2.
61 It therefore appears that VEGFR2 is the principal signal-
ling pathway for VEGF-A- and VEGF-C-mediated increased per-
meability. However, the anti-angiogenic isoforms of VEGF, such as
VEGF165b, can also increase Lp acutely and appear to do so
through the activation of VEGFR1, not VEGFR2.
27 In endothelial
cells in culture and in vivo, VEGFR2 is phosphorylated inside 2 min
after the addition of VEGF-A,
72,73 and this phosphorylation is required
for the acute and chronic phases of the increase in permeability.
70
VEGFR2 phosphorylation results in initiation of a series of signalling
pathways including increased intracellular calcium,
74,75 src acti-
vation,
72,76 and stimulation of the p42/p4MAPK pathway
77 and the
PI3 kinase pathway.
78
3.2.2 Increased intracellular Ca
21
A series of detailed experiments examining how calcium was involved
in the VEGF response have indicated that VEGFR2 activation by
VEGF-A stimulates phospholipase C activation and production of
DAG and IP3.
79 However, it appears to be the DAG production
that is responsible for the acutely increased calcium and Lp, and
this acts independently of calcium store release,
80 but through acti-
vation of the store-independent TRPC3/6 channels.
81 This has now
been shown to be the case in vitro for human microvascular endo-
thelial cells (HMVEC),
82 a microvascular endothelial cell type, but
the calcium response is much slower than in vivo, and there is evidence
that in HUVECs, the response to VEGF is dependent on calcium
store-mediated TRPC1 channels,
83 indicating that there is a signiﬁcant
difference between endothelial cell types. It has now been shown that
in HMVECs inhibition of TRPC6 by a dominant negative over-
expression inhibits the calcium response, but also endothelial cell
migration and tube formation induced by VEGF.
84,85
3.2.3 Src activation
VEGF also activates src kinase in endothelial cells in culture,
72 and
inhibition of src kinase inhibits Evans blue extravasation induced by
VEGF,
76 suggesting that src may also be required for the increase in
permeability. However, there is no clear separation yet between
src-dependent VEGF-mediated extravasation and VEGF-mediated
permeability and this remains to be seen.
3.2.4 Subcellular localization
VEGFR can be localized to caveolae in endothelial cells, and this
appears to form part of a signalling complex, or signalplex, that regu-
lates the downstream signalling. There is a close association between
the structural protein caveolin and the C-terminal of VEGFR2,
86
including PLCg
87 and hence DAG, eNOS,
88 and the TRPC6,
89 and
downstream signalling pathways such as protein kinase Ca, Raf-1,
MAPK kinase 1/2, and ERK2/1.
90 Moreover, it has recently been
shown that the lipid raft associated proteins such as the
store-operated calcium channel Orai, and the scaffolding protein
Stim can also interact with receptor-operated calcium channels such
as TRPC6 to couple both receptor-operated and store-operated
calcium entry in microdomains within the cell,
91 thus providing a mol-
ecular mechanism through which VEGF signalling could depend upon
the components of the signalplex for its mechanisms of cation entry.
Thus if VEGFRs are activated outside the caveolae, then the associ-
ated TRPC6/Orai activation would lead to a Stim-dependent recruit-
ment to the lipid raft/caveolar domain to initiate a signalling pathway
that may be different from that when TRPC6 is dissociated from the
caveolae. The concept that a co-ordinated regulation of caveolar sig-
nalling is central to the mechanisms and subsequent downstream sig-
nalling regulating permeability is becoming clearer, but their link to
increased vascular permeability has still not shown. The rapidity of
the activation of increased permeability in vivo, particularly compared
with in vitro signalling, suggests that the components involved must be
very closely associated, and it is perhaps no coincidence that the
density of caveolae in microvessels in vivo is substantially higher than
in cultured endothelial cells.
3.3 Ultrastructural changes
VEGF activation of endothelial cells in vivo and in vitro results in marked
ultrastructural changes that follow the appropriate time course for
the permeability responses.
3.3.1 Vesicular vacuolar organelles to gaps
One of the ﬁrst ultrastructural changes to be described for VEGF was
the formation of clusters of linked vesicles through endothelial cells
thought to link the luminal and abluminal surfaces.
92 These vesicular
vacuolar organelles (VVOs) occur very rapidly after activation with
VEGF (within a few seconds) in vivo.
93 The VVO formation is seen
by electron microscopy and has been shown to consist of fenestrated
linked caveolar vesicles. Perfusion of electron dense molecules (e.g.
ferritin) has shown that VVOs can contain macromolecules, and
thus they are thought to form pathways for ﬂuid and solute move-
ment across the vessel wall during VEGF-mediated permeability
increase.
94 Perfusion of single vessels in frogs and rats with VEGF
has also shown the presence of transcellular gaps running close to
but not at the endothelial cell junction, as well as intercellular gaps
at the cell junction themselves.
95 It is not known whether these pro-
cesses are part of the same mechanism and that VVOs are pre-
cursors of transcellular gaps, or whether the processes are entirely
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96 but what is clear is that large holes can appear in endo-
thelial cell barrier in response to VEGF and that this can occur
within a few seconds after administration of VEGF.
3.3.2 Junctional changes
As discussed above, addition of VEGF in endothelial cells in vitro
results in differing responses from endothelial cells in vitro, and this
also applies to the effect on endothelial junctions. In vitro within
60 min a reduction in staining of junctional proteins such as ZO1,
97
occludin,
47 VE-cadherin
47,98 at the endothelial junctions, coincident
with the onset of increased vascular permeability, and prevention of
endothelial junctional changes inhibit the VEGF permeability
response. These changes are not apparent at 5 min after the activation
of VEGF,
97 but VE-cadherin is phosphorylated at 5 min after the
addition of VEGF to endothelial cells in culture
98 (earlier time
points have not been investigated). However, in vivo changes in immu-
noﬂuorescence staining of junctional proteins have been less well
described, making it difﬁcult to associate the time-dependent
changes in vivo with those in vitro. Ultrastructural studies show that
there is a loss of junctional integrity with VEGF activation very
rapidly, and there is loss of tight and adherens junctions,
95 widening
of the cleft, and in many cases micron-sized gaps and VVOs
through endothelial cells,
99 and mathematical modelling of the
VEGF response predicts an opening of the tight junctional strands.
52
3.3.3 Fenestrae
VEGF in vivo and in vitro induces the formation of fenestrations,
100
again many minutes after the initial transient increase in permeability,
but consistent with the development of a chronic increase. This is also
seen in endothelial cells in culture, where fenestrations have been
described in response to VEGF treatment over 1–24 h.
101,102
3.4 The link from the signalplex to the
structural changes
3.4.1 eNOS
One of the earliest demonstrated downstream signal targets of VEGF
activation was endothelial nitric oxide synthase.
28,103 eNOS has been
shown to be required for VEGF-mediated increased solute per-
meability.
63 In isolated perfused rat coronary venules, eNOS inhibition
resulted in a signiﬁcant decrease in the transient increase in solute
permeability to albumin induced by VEGF, conﬁrming its role as a
downstream target involved in the permeability pathways. Subsequent
work has identiﬁed soluble guanylyl cyclase as the NO-activated
target involved in this transient increase in solute permeability
63 and
extravasation of dye.
104 The sGC activation results in the conversion
of GTP to cGMP, which activates protein kinase G (PKG) which also
appears to be required for the permeability increase.
63 The down-
stream targets for protein kinase G (PKG) have not yet been
identiﬁed.
3.4.2 Rho/Rac/Cdc42
Members of the Ras superfamily of small GTPases have been impli-
cated in the regulation of permeability by many agents. These are
prime candidates for the connection between VEGFR signalling and
the ultrastructural changes that occur in response to VEGF. VEGFR,
as part of its caveolin complex is associated with ARF6, which also
regulates Rac1 activity in membrane rufﬂing and actin cytoskeleton
dynamics.
105 The Rho kinase, ROCK is also activated by VEGF, and
appears to be required for the transient solute permeability
response.
106 Activation of ROCK results in phosphorylation of
RhoGTPases including Rho, Rac, and Cdc42. These have been
clearly identiﬁed as regulators of cytoskeletal element within the
cell, and classically Rac is required for lamellipodia protrusion, Rho
promoting assembly of actin stress ﬁbres, and Cdc42 contributing
to ﬁlopodia and membrane rufﬂes. In endothelial cells in culture,
the different members of the family have different functions, with
Rho resulting in stress ﬁbre formation, Rac and CDC42 forming
actin bundles and lamellipodia.
107 It is not yet clear how any of
these processes may be involved in the regulation of permeability,
but it has been suggested from in vitro endothelial experiments that
the polymerization of actin can result in cell retraction which could
lead to an increase in tension on the intercellular junctions,
108 and
hence a force for disassociation of the adherens junctions as described
below or for generation of actin-dependent contraction of areas of
endothelial cells to form transcellular gaps. Rac in particular appears
to be linked to VEGF-induced fenestration formation.
109 While
these associations have been made there is as yet no clear evidence
for how cell cytoskeletal changes are linked to barrier changes in
endothelial cells in vivo, or how these link to VEGF.
3.4.3 VE-cadherin
VEGF activation of endothelial cells results in phosphorylation and dis-
assembly of VE-cadherin, one of the principal signalling and structural
proteins associated with the adherens junction that forms part of the
intercellular cleft.
110 VE-cadherin phosphorylation is initiated within
5 min, but peaks at 30 min after activation by VEGF in endothelial
cells in culture. It is thus able to be responsible at least in part for
the chronic increase in permeability, but is too slow to account for
the acute increase seen in response to VEGF. The contribution of
VE-cadherin to vascular permeability in vivo is not as clearly estab-
lished as in the in vitro models. There is considerable evidence that
the adherens junction itself is regulated by VEGF during alterations
in vascular permeability,
111 but whether it structurally forms a
barrier to ﬂuid or protein ﬂux, is a component of the extracellular
matrix, or whether it is primarily a signalling function is still not
clearly demonstrated in vivo. For instance, it has recently been
shown that the tight junction can be regulated by VE-cadherin signal-
ling.
112 Additional data show that VEGF mediates a dephosphorylation
of VE-cadherin, which disassociates from src and Csk a negative reg-
ulator of src, thus enabling src to be activated. This would ﬁt with a
dual mechanism of VEGF-induced permeability—a transient initial
calcium dependence, followed by the activation of src, FAK, and
VE-cadherin, followed by a cadherin-dependent signalling pathway
through the tight junction that involves src activation for the
chronic effect.
113
3.4.4 Zona occludens-1 and occludin
The tight junction barrier has been closely linked with contributing to
maintenance of permeability through a number of studies linking tight
junctional barrier presence to baseline permeability in different
organs.
114 However, recent work indicates that the role of the tight
junction may be to provide a narrowing of the ﬂuid exit pathway, reg-
ulating junctional ﬂuid velocity, and hence providing a restriction to
both protein and ﬂuid ﬂux by maintaining an oncotic reﬂection coefﬁ-
cient as well as its role as a regulator of ﬂuid and solute ﬂux.
115 There
is good evidence that in vitro VEGF activation stimulates phosphoryl-
ation of the tight junctional regulator Zona occludens-1 (ZO-1),
97
and it has been suggested that this mediates the VEGF-mediated
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50 Again, however, the phosphorylation
of the ZO-1 takes 15–30 min in vitro, too long to account for the
acute increase in permeability. There are no data on the time
course of VEGF-mediated phosphorylation of ZO-1 in vivo.
3.4.5 PV1
VEGF induces fenestration in endothelial cells in vitro within  30 min
of activation,
101 and in fenestrated tissues, the inhibition of VEGF165-
mediated activation of VEGFR2 either by overexpression of the
anti-angiogenic isoform VEGF165b
116 or by administration of VEGFR
tyrosine kinase inhibitors
117 or VEGF blocking antibodies
118 results
in a reduction in the fenestral density and reduction in the hydraulic
conductivity and dye extravasation. Fenestrae in many vascular beds
are spanned by a diaphragm formed from the protein PV1.
119 PV1
has been shown to be both induced and repressed by VEGF, indicating
that this may also contribute to the chronic increase in permeability
brought about by VEGF. Again this is too slow to account for the
acute increase, but may be responsible for the high hydraulic conduc-
tivity maintained in many fenestrated vascular beds in which VEGF is
constitutively produced (e.g. salivary gland, adrenal gland, ovary, pitu-
itary, etc.).
There is therefore a dichotomy between in vivo and in vitro exper-
iments, and a biphasic response to VEGF. However, VEGF expression
can occur either as a sudden onset of VEGF or as a gradual response
as the VEGF concentration increases or decreases in response to
physiological or pathophysiological stimuli. Interestingly, there is yet
to be a clear and concise assessment of how such effects of VEGF
on permeability, investigated through multiple arbitrary systems—
from bolus administration of VEGF to isolated microvessels in vivo,
injection into skin, or application to endothelial cells in culture—
apply to the VEGF seen by blood vessels during pathological and phys-
iological states.
4. Consequences of the effects
of VEGF on permeability
4.1 Physiological effects
4.1.1 Reproduction
VEGF is highly expressed during the menstrual cycle in a manner that
facilitates follicle maturation from primary to secondary antral follicles
and during corpus luteal development following ovulation.
120 More-
over, the growing endometrium induces a strong VEGF driven vascu-
larization in readiness for implantation of the fertilized embryo. As the
mammary glands remodel the mammary alveolar epithelium, massive
angiogenesis occurs, which provides sufﬁcient vasculature to generate
milk.
121 The permeability of the capillaries is extremely variable. Endo-
metrial and corpus luteal vessels are relatively tight with permeabil-
ities approaching normal continuous vessels, ovarian theca interna
vessels are highly fenestrated and are thought to contribute to follicu-
lar ﬂuid formation. The mammary gland vasculature is variable with
alveolar epithelium fenestrated, but ductal epithelium tight, despite
both vascular beds seeing continuous high concentrations of VEGF.
122
4.1.2 Wound healing
VEGF is also highly expressed during wound healing and the per-
meability of vessels growing into the wound is raised compared
with normal, is fenestrated, and contains large transcellular gaps,
123
but recent studies on patients undergoing treatment with anti-VEGF
antibodies do not report wound healing side effects.
124
4.1.3 Glomerular function
In the glomerulus on the other hand, there is a high vascular per-
meability, in particular the hydraulic conductivity of the endothelium,
in response to substantial VEGF secretion and production by the
peri-endothelial podocytes. VEGF inhibition can lead to breakdown
of glomerular function, and this may be due to the effects of VEGF
on endothelial fenestrations combined with its survival effects on
podocytes themselves.
125 A similar story can be painted for other
tissues with high-VEGF expression including salivary gland adrenal
cortex and pituitary gland—high secretion rates but no angiogenesis.
It therefore appears that in the physiological system the two pathways
are kept separate.
4.2 In disease
In contrast to VEGF-driven physiological angiogenesis where excess
ﬂuid formation is rarely seen or VEGF-induced physiologically
increased permeability where angiogenesis is rarely seen, in disease
states VEGF overexpression often leads to excess of both actions.
4.2.1 Cancer: ascites, cerebral oedema, and so on
VEGF expression driven by hypoxia is considered to be a principal
inducer of increased vascular supply to tumours. VEGF expression
in tumours is as high or higher than seen in most normal states
where VEGF expression is substantial (e.g. renal glomerulus or
corpus luteum). The VEGF produced drives not only angiogenesis
but also increased vascular permeability and resulting oedema. Inhi-
bition of VEGF in brain tumours,
126 ovarian carcinoma,
127 as well as
in benign conditions such as vestibular Schwannomas, reduces the
ﬂuid efﬂux around the tumours, reducing morbidity, and in the case
of hearing loss associated with vestibular Schwannomas, restoring
normal function.
128 In fact the contribution of reduced vascular per-
meability to the effect of anti-VEGF agents has not yet been clearly
discriminated from their anti-angiogenic actions, and as will be seen
below may actually be a more important effect.
4.2.2 Blindness: diabetic macular edema (DME), wet
age-related macular degeneration
VEGF is also over-expressed in two key causes of blindness in the
western world, neovascular (or wet) age-related macular degener-
ation (wAMD) and diabetic retinopathy. These two conditions have
very different fundamental causes. wAMD results from a build-up of
lipid deposits in the retinal pigmented epithelial cells of the retina,
and progressive breakdown of the underlying Bruch’s membrane.
Increased VEGF expression results in a neovascularization from the
underlying choroidal vasculature into the retina.
129 Whereas retinal
blood vessels are part of the blood brain barrier and have extremely
low hydraulic conductivity,
130 the choroidal vasculature has a very
high permeability partly due to the presence of fenestrations in the
endothelial cells
130 (which may be maintained by constitutive VEGF
expression from the basolateral part of the retinal pigmented epi-
thelial cells). When these choroidal vessels invade into the retina,
the increased vascular permeability results in sub-retinal oedema,
which results in a rapid loss of sight (over a few weeks to months).
Intraocular injection with either bevacizumab or the variable fragment
of a similar VEGF antibody, termed ranibizumab, can initially reverse
the vision loss and then maintain vision.
131 This is associated with a
VEGFs and vascular permeability 267resolution of the sub-retinal oedema, indicating that it is the anti-
permeability properties of VEGF therapy that is effective at least
initially in this disease.
The second leading cause of blindness in the developed world is
diabetic retinopathy. This has quite a different aetiology from AMD
but is also VEGF dependent. The endothelial dysfunction associated
with diabetes occurs systemically, resulting in loss of endothelial
cells from the retina and localized areas of ischaemia.
132 This results
in hypoxic upregulation of VEGF, which acts on the vasculature that
is still perfused in the periphery of the ischaemic area to produce a
proliferation and increased leakage of vessels resulting in haemor-
rhage, oedema, and neovascularization intraretinally causing disrupted
vision.
133 Anti-VEGF therapies are being tried in diabetic retinopathy,
and particularly in the form of retinopathy that results in demon-
strable ﬂuid formation in the retina—diabetic macular oedema and
phase II trials have been promising for ranibizumab. Proliferative dia-
betic retinopathy is a more complicated initial target because VEGF
inhibition results in endothelial cell regression and vascular loss in
animal models, which is a potential hazard for diabetic patients
where endothelial loss is an underlying cause of the disease.
4.2.3 Other conditions
VEGF-mediated permeability has also been implicated in renal failure,
arthritis, psoriasis, and coronary disease, but their consideration is
beyond the scope of this review.
5. Conclusion
5.1 Importance of VEGF antagonists
in clinical situations
The increasingly widespread use of VEGF antagonists in clinical con-
ditions, in particular, in cancer and eye disease, has focused attention
on how these antagonists exert their effects. It has been presumed
that as VEGF is a potent angiogenic agent, the effects are mediated
through this mechanism. However, it is increasingly becoming the
case that anti-VEGF agents are acting on the symptoms of the
disease by blocking the VEGF-mediated increase in permeability
rather than any direct effect on angiogenesis. In AMD, DME,
gliomas, ovarian carcinoma, and lung cancer, this is probably the prin-
cipal mechanism of action, and it is still unknown even in the most
widely known cancer—colorectal cancer—how much is due to anti-
angiogenesis and how much is due to increased permeability. The
recent interest in mechanisms of escape of tumours from ‘anti-
angiogenic’ therapy are built on the premise that the inhibition of
tumour growth was due to anti-angiogenesis, whereas if it was due
initially to reduced vascular permeability, then the effect is not so
much ‘escape from anti-angiogenic therapy’ but unaffected angiogen-
esis now overcoming the effects of reduced permeability.
5.2 Synthesis of current knowledge
to summarize best case
VEGF-mediated permeability experimentally appears to occur in a
biphasic manner both in vitro and in vivo, although these two time
courses do not compare. The molecular mechanisms underlying this
increase in permeability are still not clear, not least due to the difﬁ-
culty in reconciling different methodologies of permeability measure-
ment, with the respective changes in molecular interactions. We still
do not know if src activation, for instance, in vivo occurs within a time
frame of the acute increase in permeability or is only required for the
chronic response. We do not know whether the ultrastructural fea-
tures seen initially in vivo (VVOs, gaps) are consistent with altered
junctional properties measured in the long term. It therefore
appears to be critical for the effect of VEGF on permeability to be
examined with care to the timing of the response when investigating
the molecular mechanisms, and not to over-interpret in vitro results to
the in vivo situation. Equally there is a danger in assuming that abrupt
VEGF application to a tissue represents a physiological or even patho-
logical state and that VEGF expression in vivo occurs in a more diffuse
and gradual time scale, which needs to be reproduced experimentally
to investigate the mechanisms underlying the permeability changes
that are clearly important clinically.
5.3 Future directions
The synthesis of existing molecular changes is becoming more and
more difﬁcult to reconcile with the generation of results that are
not comparable across systems. Endothelial cells from different vascu-
lar beds are not the same, and cells in identical vascular beds can
respond differently according to their environment—oxygen
tension, shear stress, circulating leucocyte interactions, etc. Finally,
the transport of molecules across the endothelial wall is dependent
on multiple factors in addition to the barrier properties of that wall.
It will therefore be critical in the future to be able to build a molecular
picture of VEGF-mediated permeability that is speciﬁc for vascular
beds, that is dependent on the application process (i.e. how quickly
VEGF levels rise), and that actually reﬂects changes in the barrier func-
tion of the endothelium, the VEGF type, the vascular wall history, and
the response time. Until that is clearly laid out for each new ﬁnding,
building up a picture of how VEGF increases permeability will still
be an inexact science. Moreover, while there have been numerous
qualitative descriptions of the relative signalling pathways to the
VEGF-mediated increase in permeability, there is still very little
known about the quantitative contribution of these signalling path-
ways, for instance, are src and Ca
2+ responses additive or synergistic?
Perhaps the key area required for investigation is the dissection of the
signalplex involving VEGF receptors, ion channels, and scaffolding pro-
teins that regulate the signalling pathways downstream, for while this
is being resolved for angiogenesis, it is some way off for permeability.
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